| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H24O2 |
| Molecular Weight | 332.4355 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)CCC(C)(C)C2=CC(=CC=C12)C#CC3=CC=C(C=C3)C(O)=O
InChI
InChIKey=OQVLOWLEEHYBJH-UHFFFAOYSA-N
InChI=1S/C23H24O2/c1-22(2)13-14-23(3,4)20-15-17(9-12-19(20)22)6-5-16-7-10-18(11-8-16)21(24)25/h7-12,15H,13-14H2,1-4H3,(H,24,25)
| Molecular Formula | C23H24O2 |
| Molecular Weight | 332.4355 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
EC23, also known as AGN 190205, is photostable synthetic analog of All-trans retinoic acid (ATRA). EC23 is an agonist of retinoic acid receptors: alpha, beta and gamma, while having no appreciable activity for retinoid X receptors and weakly activates aryl hydrocarbon receptor. It was shown, that EC23 induced neural differentiation in human pluripotent embryonic stem cells.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.4 nM [EC50] | |||
| 0.5 nM [EC50] | |||
| 41.0 nM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
